Congruence Therapeutics Overview
- Founded
- 2021
- Status
- Private
- Employees
- 11
- Latest Deal Type
- Series A
- Latest Deal Amount
- $50M
- Investors
- 7
Congruence Therapeutics General Information
Description
Developer of a pharmacological stabilizer intended for the treatment of rare diseases. The company uses the interface of computational and experimental drug discovery, structural bioinformatics, computational chemistry, and machine learning to deploy an in silico platform that enables the design of a validated class of small molecules, helping researchers to design novel small molecules for diseases of protein misfolding.
Contact Information
- Montreal, Quebec
- Canada
Congruence Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Seed Round | 08-Feb-2022 | $50M | 0000 | Completed | Startup |
Congruence Therapeutics Executive Team (4)
Congruence Therapeutics Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Nancy Harrison | Congruence Therapeutics | Board Member | 000 0000 |
Congruence Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCongruence Therapeutics Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Amplitude Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Clarissa Desjardins | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Driehaus Capital Management | Corporation | Minority | 000 0000 | 000000 0 | |
Fonds de solidarité FTQ | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Investissement Québec | Venture Capital | Minority | 000 0000 | 000000 0 |